Review of Gene Therapy Clinical Trials for Retinal Diseases.

Competing Interests: A.A.A. reports other from Regenxbio, outside the submitted work; paid internship. H.K. reports other from Genentech, outside the submitted work; paid internship. A.M.K. reports personal fees from AbbVie, grants and personal fees from Adverum Biotechnologies, personal fees from AGTC, personal fees from Alimera Sciences, personal fees from Allergan, grants and personal fees from Apellis Pharmaceuticals, personal fees from Arrowhead Pharmaceuticals, personal fees and other from Aviceda Therapeutics, personal fees from Bausch & Lomb, personal fees from Broadwing Bio, personal fees from Clearside Biomedical, grants and personal fees from 4D Molecular Therapeutics, grants and personal fees from Eyepoint Pharmaceuticals, personal fees from Fronterra Therapeutics, grants and personal fees from Gemini Pharmaceuticals, grants and personal fees from Genentech, grants and personal fees from Gyroscope Therapeutics, grants and personal fees from Iveric Bio, grants and personal fees from Janssen Pharmaceuticals, personal fees from Kato Pharmaceuticals, grants and personal fees from Kodiak Sciences, grants and personal fees from Ocular Therapeutix, grants and personal fees from Oculis, grants and personal fees from Ocuterra, grants and personal fees from Opthea, grants and personal fees from Oxurion, grants and personal fees from Novartis, personal fees from Perfuse, personal fees and other from PolyPhotonix, personal fees from Ray Therapeutics, grants, personal fees and other from Recens Medical, personal fees from Regeneron Pharmaceuticals, grants and personal fees from Regenxbio, grants and personal fees from Roche, personal fees from Stealth Biotherapeutics, personal fees from Thea Pharma, grants and personal fees from Unity Biotechnology, personal fees from Vanotech, personal fee and other from Vial, grants from Annexon Biosciences, grants from Neurotech, grants from NGM Biopharmaceuticals outside the submitted work. The remaining authors declare that they have no conflicts of interest to disclose.